Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 45

1.

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.

Adjei AA, Richards D, El-Khoueiry AB, Braiteh F, Becerra C, Stephenson J, Hezel AF, Sherman M, Garbo LE, Leffingwell DP, Iverson C, Miner JN, Shen Z, Yeh LT, Gunawan S, Wilson DM, Manhard KJ, Rajagopalan P, Krissel H, Clendeninn NJ.

Clin Cancer Res. 2015 Dec 7. pii: clincanres.1681.2015. [Epub ahead of print]

PMID:
26644411
2.

Corrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.

Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Deshpande V, Zhu AX, Hezel AF, Yen KE, Straley KS, Travins J, Popovici-Muller J, Gliser C, Ferrone CR, Apte U, Llovet JM, Wong KK, Ramaswamy S, Bardeesy N.

Nature. 2015 Dec 3;528(7580):152. doi: 10.1038/nature16136. Epub 2015 Nov 18. No abstract available.

PMID:
26580013
3.

Genetics and Biology of Pancreatic Ductal Adenocarcinoma.

Dunne RF, Hezel AF.

Hematol Oncol Clin North Am. 2015 Aug;29(4):595-608. doi: 10.1016/j.hoc.2015.04.003. Epub 2015 Jun 10. Review.

PMID:
26226899
4.

Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).

Ramanathan RK, McDonough SL, Kennecke HF, Iqbal S, Baranda JC, Seery TE, Lim HJ, Hezel AF, Vaccaro GM, Blanke CD.

Cancer. 2015 Mar 30. doi: 10.1002/cncr.29363. [Epub ahead of print]

PMID:
25827820
5.

Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.

Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R, Benes C, Engelman JA, Bardeesy N.

Clin Cancer Res. 2015 Jan 15;21(2):396-404. doi: 10.1158/1078-0432.CCR-14-1591. Epub 2014 Oct 27.

6.

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.

Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Deshpande V, Zhu AX, Hezel AF, Yen KE, Straley KS, Travins J, Popovici-Muller J, Gliser C, Ferrone CR, Apte U, Llovet JM, Wong KK, Ramaswamy S, Bardeesy N.

Nature. 2014 Sep 4;513(7516):110-4. doi: 10.1038/nature13441. Epub 2014 Jul 2. Erratum in: Nature. 2015 Dec 3;528(7580):152.

7.

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.

Hezel AF, Noel MS, Allen JN, Abrams TA, Yurgelun M, Faris JE, Goyal L, Clark JW, Blaszkowsky LS, Murphy JE, Zheng H, Khorana AA, Connolly GC, Hyrien O, Baran A, Herr M, Ng K, Sheehan S, Harris DJ, Regan E, Borger DR, Iafrate AJ, Fuchs C, Ryan DP, Zhu AX.

Br J Cancer. 2014 Jul 29;111(3):430-6. doi: 10.1038/bjc.2014.343. Epub 2014 Jun 24.

8.

Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression.

Kinsey C, Balakrishnan V, O'Dell MR, Huang JL, Newman L, Whitney-Miller CL, Hezel AF, Land H.

Cell Rep. 2014 May 22;7(4):1143-55. doi: 10.1016/j.celrep.2014.03.061. Epub 2014 May 1.

9.

Stereotactic body radiation therapy as a bridge to transplantation and for recurrent disease in the transplanted liver of a patient with hepatocellular carcinoma.

Mazloom A, Hezel AF, Katz AW.

Case Rep Oncol. 2014 Jan 10;7(1):18-22. doi: 10.1159/000357801. eCollection 2014 Jan.

10.

New and emerging treatment options for biliary tract cancer.

Noel MS, Hezel AF.

Onco Targets Ther. 2013 Oct 30;6:1545-52. doi: 10.2147/OTT.S32545. Review.

11.

Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma.

Goyal L, Supko JG, Berlin J, Blaszkowsky LS, Carpenter A, Heuman DM, Hilderbrand SL, Stuart KE, Cotler S, Senzer NN, Chan E, Berg CL, Clark JW, Hezel AF, Ryan DP, Zhu AX.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1305-14.

PMID:
24121453
12.

Diabetes mellitus impacts risk of macrovascular invasion in patients undergoing transplantation for hepatocellular carcinoma.

Connolly GC, Safadjou S, Kashyap R, Chen R, Orloff MS, Hezel AF.

BMC Gastroenterol. 2013 Jan 14;13:9. doi: 10.1186/1471-230X-13-9.

13.

Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability.

Mondo EL, Noel MS, Katz AW, Schoeniger LO, Hezel AF.

J Clin Oncol. 2013 Jan 20;31(3):e37-9. doi: 10.1200/JCO.2012.44.0339. Epub 2012 Dec 10. No abstract available.

14.

Diabetes mellitus is associated with the presence of metastatic spread at disease presentation in hepatocellular carcinoma.

Connolly GC, Safadjou S, Chen R, Nduaguba A, Dunne R, Khorana AA, Hezel AF.

Cancer Invest. 2012 Dec;30(10):698-702. doi: 10.3109/07357907.2012.732162. Epub 2012 Oct 16.

PMID:
23072586
15.

TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progression.

Hezel AF, Deshpande V, Zimmerman SM, Contino G, Alagesan B, O'Dell MR, Rivera LB, Harper J, Lonning S, Brekken RA, Bardeesy N.

Cancer Res. 2012 Sep 15;72(18):4840-5. doi: 10.1158/0008-5472.CAN-12-0634. Epub 2012 Jul 11.

16.

Autophagy in intra-hepatic cholangiocarcinoma.

Huang JL, Hezel AF.

Autophagy. 2012 Jul 1;8(7):1148-9. doi: 10.4161/auto.20647. Epub 2012 Jul 1.

17.

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.

Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik JH, Lim C, Guimaraes AR, Martin ES, Chang J, Hezel AF, Perry SR, Hu J, Gan B, Xiao Y, Asara JM, Weissleder R, Wang YA, Chin L, Cantley LC, DePinho RA.

Cell. 2012 Apr 27;149(3):656-70. doi: 10.1016/j.cell.2012.01.058.

18.

Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy.

Alexander BM, Fernandez-Del Castillo C, Ryan DP, Kachnic LA, Hezel AF, Niemierko A, Willett CG, Kozak KR, Blaszkowsky LS, Clark JW, Warshaw AL, Hong TS.

Gastrointest Cancer Res. 2011 Jul;4(4):116-21.

19.

Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.

O'Dell MR, Huang JL, Whitney-Miller CL, Deshpande V, Rothberg P, Grose V, Rossi RM, Zhu AX, Land H, Bardeesy N, Hezel AF.

Cancer Res. 2012 Mar 15;72(6):1557-67. doi: 10.1158/0008-5472.CAN-11-3596. Epub 2012 Jan 20.

20.

Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.

Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW.

Oncologist. 2012;17(1):14. doi: 10.1634/theoncologist.2011-0452. Epub 2011 Dec 30.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk